❤️‍🩹 Personalized Cancer Vaccines Arrive

Editors’ Note: Our website features a healthspan-focused job board, an archive of past newsletters, a growing dictionary of terms we’ve highlighted in previous editions and more to come!

Visit us at: https://stacked-health.com/

Or copy and paste this link to others: {{rp_refer_url}}

I quit my afternoon coffee. Not because I wanted to — because I found something better.

You know that wall you hit every day around 2–3 PM? I used to just accept it as the cost of doing anything. Another coffee, a quick spike, then the crash — and somehow I'd still feel dehydrated by dinner.

Then I tried X·E Fountain, Pique's brand-new electrolyte energy drink, and I genuinely wasn't ready for how good "no crash" could feel.

No caffeine jitters. No 4 PM slump. Just clean, steady energy that actually hydrates me instead of draining me. It's built with a premium Vitamin B Complex for natural cellular energy, Magnesium Malate + Taurate for real focus, and a full electrolyte blend that makes it feel like a treat, not a chore.

The cucumber-celery-lime flavor is so crisp and refreshing — it's basically stolen my afternoon coffee slot completely.

For launch, get 15% off for life

Your immune system is talented at finding things that do not belong. It patrols every hour of your life, inspecting cells, and when it finds a virus it goes to work without being asked.

Cancer walks past it. The reason is uncomfortable once you sit with it. A tumor is not an invader. It is built from your own cells, running your own DNA, carrying all the same identification everything else carries. Your immune system checks it, reads it as you, and keeps moving. That is the oldest problem in oncology, and it is why cancer was treated for most of a century with knives and poison. There was nothing specific to aim at.

The mistakes that give it away

Tumors are sloppy, and that turns out to be the opportunity.

A cancer cell grows by copying itself over and over, and every round of copying introduces errors into its DNA. Most of those errors do nothing. Some of them change the recipe for a protein, so the cell starts producing a slightly misspelled version of something ordinary.

Every cell in your body constantly displays little fragments of the proteins it is making on its outer surface, holding them up for passing immune cells to inspect. Think of it as a cell showing its work. Healthy cells hold up fragments the immune system has seen since birth and learned to ignore. A cancer cell holds up fragments of those misspelled proteins, and those look wrong.

Those misspelled fragments are called neoantigens, meaning new antigens (an antigen is just anything the immune system can recognize and target). They appear nowhere else in your body.

The catch is that the target is different for every person. Two people diagnosed with the same cancer on the same day will be carrying almost entirely different mutations, which means almost entirely different neoantigens. There is no product you can make once and sell to everybody.

Building a drug out of one person's tumor

Which means you build it one person at a time.

A surgeon removes the tumor. A piece of it gets sequenced, and that sequence is compared against the patient's healthy DNA. The goal is to isolate the mutations that belong only to cancer. Software then predicts which of those mutations produce fragments the immune system is most likely to actually notice, since not all of them will. Up to 34 of the best candidates get selected.

Those 34 targets are then written into a single strand of mRNA, packaged, and injected. Your own cells read the instructions, manufacture the fragments, and hold them up for inspection. Your immune system meets them, learns the shape, and starts hunting for anything else in your body wearing that signature. The only things wearing it are the cancer cells that surgery missed.

This is the same technology as the COVID vaccines. The manufacturing platform is identical. One is made in bulk to teach your body about a virus it has not met. This one is made for you, from you, to teach your body about a tumor it already has.

The drug is called intismeran autogene, and it is given alongside Keytruda (pharma/biotech never make the names easy), which does a complementary job. Tumors defend themselves by pressing a chemical brake that shuts down immune cells attacking them. Keytruda releases that brake. The vaccine says what to look for, and Keytruda keeps the immune system from being switched off once it finds it.

What happened on August 19

Merck and Moderna announced that the combination had won a Phase 3 trial. It is the first individualized cancer therapy of this kind to win a Phase 3, and the first mRNA cancer treatment to do so.

The trial enrolled 1,137 people who had melanoma surgically removed and who were at high risk of it returning. Two out of every three received intismeran plus Keytruda. The remaining third received Keytruda by itself, which is what these patients would get today.

The combination beat Keytruda alone on how long people went before their cancer came back, and on how long they went before it spread to distant organs. No new safety problems turned up. 

This was not tested against a placebo or against nothing. It was tested against the current standard of care and it improved on it, which is a much harder thing to do and a much more useful thing to know.

Why nobody can keep this on a shelf

Every drug you have ever taken was made in a batch and stored until you needed it. This one cannot be.

Nothing can be produced in advance because the product does not exist until someone's tumor is sequenced. Each patient needs sequencing, target selection, mRNA synthesis, packaging, and safety testing, and reported turnaround sits somewhere around six weeks. Neither company has published an official timeline. The squeeze is that treatment after surgery is supposed to start reasonably soon after surgery, so the manufacturing clock eats directly into the treatment window.

Keytruda by itself runs somewhere around $220,000 across the course used in this trial. Intismeran goes on top of that, and no price exists yet.

The closest precedent is CAR-T, the cancer therapy that also has to be custom built for each patient. CAR-T did eventually scale, but it took years and it still mostly happens inside a small number of specialized centers. Melanoma surgery happens nearly everywhere.

The odd politics sitting on top of this

In August 2025, the Department of Health and Human Services cancelled 22 mRNA vaccine projects worth close to $500 million, arguing the platform underperforms against respiratory viruses. The same department has since backed a roughly $200 million effort aimed at vaccines that stop cancer from coming back.

The technology is being defunded for infections and funded for cancer, which is a strange place to land given that the underlying machinery is the same in both cases. It is worth watching because the science just cleared its highest bar, yet the policy around it is being decided on completely separately.

Why you should care

Personalization is the loudest promise in health right now. Monitors that tailor your diet, panels that tailor your supplements, algorithms that tailor your training. Almost none of it has ever been put in a randomized trial against a real alternative with a hard outcome at the end.

This was, and it worked. That makes it the strongest evidence we have that building a treatment from one person's own molecular data can beat a good standard one.

What made this necessary was a target that provably exists in one person and provably does not exist in anyone else, plus a clear mechanism explaining why hitting that target changes what happens to them. Most personalization being sold today has neither. It has variation between people, and variation is not the same thing as a target.

This therapy only exists downstream of a tumor being found and cut out. It does nothing about whether you get cancer in the first place, and excess body fat and poor metabolic health remain established risk factors for more than a dozen cancers. Prevention and treatment are still doing separate jobs.

Nine trials are running now across lung, bladder, and kidney cancer, with lung results ahead. If those hold, this becomes a logistics story, and the bottleneck moves out of the laboratory and into the supply chain.

Or copy and paste this link to others: {{rp_refer_url}}

Current Referral Count: {{rp_num_referrals}}